Skip to content

Nebivolol

beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM

Also known as: bystolic, nebivolol HCl, nebivolol hydrochloride, vasoxen

OfpFDA approvedATC C07AB12ATC C07BB12ATC C07FB12

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Nebivolol is an ofp drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 2007. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 4 molecular targets, including ADRB1, HTR1A and ADRB2. Recorded indications include Hypertensive disorder.

  • Approval status: ofp (first approved 2007 by the FDA).
  • Drug class: beta-Adrenergic Blocker.
  • Mechanism of action: Adrenergic beta-Antagonists.
  • Molecular targets: ADRB1, HTR1A, ADRB2 and ADRB3 (4 listed in DrugCentral).
  • Indications: Hypertensive disorder.
  • ATC code: C07AB12 (Beta blocking agents, selective).
  • Molecular formula: C22H25F2NO4; molecular weight 405.44 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Hypertensive disorder

Off-label uses (4)

  • Angina pectoris
  • Atrial fibrillation
  • Chronic heart failure
  • Myocardial Reinfarction Prevention

Contraindications (13)

  • Acute nephropathy
  • Bradycardia
  • Bronchospasm
  • Cardiogenic shock
  • Complete atrioventricular block
  • Decompensated cardiac failure
  • Diabetes mellitus
  • Disease of liver
  • Hepatic failure
  • Hypoglycemic disorder
  • Peripheral vascular disease
  • Second degree atrioventricular block
  • Sick sinus syndrome

Mechanism & targets

Mechanism of action (MoA)Adrenergic beta-Antagonists
Established pharmacologic classbeta-Adrenergic Blocker

Molecular targets (4)

TargetGeneActionActivity
Beta-1 adrenergic receptorADRB1antagonistKi 8.50
5-hydroxytryptamine receptor 1AHTR1AunknownKi 8.00
Beta-2 adrenergic receptorADRB2antagonistKi 7.50
Beta-3 adrenergic receptorADRB3antagonistKi 5.66

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2007-12-17FDA—FOREST LABS

ATC classification

ATC codeTherapeutic hierarchy
C07AB12CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, selective
C07BB12CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS AND THIAZIDES › Beta blocking agents, selective, and thiazides
C07FB12CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS, OTHER COMBINATIONS › Beta blocking agents and calcium channel blockers
C09BX07CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ACE INHIBITORS, COMBINATIONS › ACE inhibitors, other combinations
C09DX05CARDIOVASCULAR SYSTEM › AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM › ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS › Angiotensin II receptor blockers (ARBs), other combinations
C10BX22CARDIOVASCULAR SYSTEM › LIPID MODIFYING AGENTS › LIPID MODIFYING AGENTS, COMBINATIONS › Lipid modifying agents in combination with other drugs

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • FDA label: CYP2D6 · No Clinical PGx
  • HCSC label: CYP2D6 · No Clinical PGx
  • Swissmedic label: CYP2D6 · Informative PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Acute kidney injury699.9
Bradycardia468.9
Hyperkalaemia328.3
Hypotension287.6
Hypertensive crisis260.9
Hyponatraemia254.2
Drug interaction218.5
Anaemia210.1
Systemic lupus erythematosus203.8
Lactic acidosis202.6
Syncope199.2
Hypokalaemia177.7

Chemical structure

Molecular formulaC22H25F2NO4
Molecular weight405.44 g/mol
CAS number118457-14-0
InChIKeyKOHIRBRYDXPAMZ-UHFFFAOYSA-N
PubChem CID71301
OC(CNCC(O)C1CCC2=CC(F)=CC=C2O1)C1CCC2=CC(F)=CC=C2O1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Nebivolol used for?

DrugCentral lists the following indications for Nebivolol: Hypertensive disorder.

How does Nebivolol work?

Nebivolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB1 (antagonist), HTR1A, ADRB2 (antagonist) and ADRB3 (antagonist).

When was Nebivolol first approved?

Nebivolol was first approved by the FDA in 2007.

What drug class does Nebivolol belong to?

Nebivolol is in the beta-Adrenergic Blocker class.

What is the chemical formula of Nebivolol?

Nebivolol has the molecular formula C22H25F2NO4 and a molecular weight of 405.44 g/mol.

Browse: all drugs starting with N · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2007-12-17
AgencyFDA
Targets4
Indications1
FormulaC22H25F2NO4
DrugCentral ID1887
Interactive profile